Meeting
2020 ASCO Virtual Scientific Program
Prostate cancer biomarker enrichment and treatment selection (PC-BETS) study: A Canadian cancer trials group phase II umbrella trial for metastatic castration-resistant prostate cancer (mCRPC).
Authors
Kim N. Chi
BC Cancer and Vancouver Prostate Centre, Vancouver, BC, Canada
Kim N. Chi , Som Mukherjee , Fred Saad , Eric Winquist , Michael Ong , Michael Paul Kolinsky , Adrian G. Sacher , Cristiano Ferrario , Muhammad Salim , Robyn Jane Macfarlane , Nayyer Iqbal , Sebastien J. Hotte , Matti Annala , Jelena Petrovic , Dongsheng Tu , Moira Katherine Rushton , Francisco Emilio Vera Badillo , Martin Smoragiewicz , Alexander William Wyatt
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT03385655, NCT02905318
Citation
J Clin Oncol 38: 2020 (suppl; abstr 5551)
DOI
10.1200/JCO.2020.38.15_suppl.5551
Abstract #
5551
Poster Bd #
132
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Prospective ctDNA genotyping for treatment selection in metastatic castration-resistant prostate cancer (mCRPC): The Canadian Cancer Trials Group phase II PC-BETS umbrella study.
First Author: Edmond Michael Kwan
Poster
2023 ASCO Genitourinary Cancers Symposium
Androgen receptor (AR) mutations in men with metastatic castration-resistant prostate cancer (mCRPC): Incidence and natural history.
First Author: Alice Bernard-Tessier
Poster
2018 ASCO Annual Meeting
Genomic profiling of primary prostate tumors from patients who develop metastatic castration-resistant prostate cancer (mCRPC).
First Author: Joaquin Mateo
Poster
2018 Genitourinary Cancers Symposium
Cell-free DNA (cfDNA) analysis and evaluation of BRAF amplifications and mutations in metastatic castration-resistant prostate cancer.
First Author: Peter Steinwald